These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

202 related articles for article (PubMed ID: 28844015)

  • 1. Impact of gene-expression profiling in patients with early breast cancer when applied outside the guideline directed indication area.
    Schreuder K; Kuijer A; Rutgers EJT; Smorenburg CH; van Dalen T; Siesling S
    Eur J Cancer; 2017 Oct; 84():270-277. PubMed ID: 28844015
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Changes over time in the impact of gene-expression profiles on the administration of adjuvant chemotherapy in estrogen receptor positive early stage breast cancer patients: A nationwide study.
    Kuijer A; Drukker CA; Elias SG; Smorenburg CH; Th Rutgers EJ; Siesling S; van Dalen T
    Int J Cancer; 2016 Aug; 139(4):769-75. PubMed ID: 27062369
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Factors Associated with the Use of Gene Expression Profiles in Estrogen Receptor-Positive Early-Stage Breast Cancer Patients: A Nationwide Study.
    Kuijer A; Schreuder K; Elias SG; Smorenburg CH; Rutgers EJ; Siesling S; van Dalen T
    Public Health Genomics; 2016; 19(5):276-81. PubMed ID: 27508402
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Initial Trends in the Use of the 21-Gene Recurrence Score Assay for Patients With Breast Cancer in the Medicare Population, 2005-2009.
    Dinan MA; Mi X; Reed SD; Hirsch BR; Lyman GH; Curtis LH
    JAMA Oncol; 2015 May; 1(2):158-66. PubMed ID: 26181015
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The influence of gene expression profiling on decisional conflict in decision making for early-stage breast cancer chemotherapy.
    MacDonald KV; Bombard Y; Deal K; Trudeau M; Leighl N; Marshall DA
    Eur J Cancer; 2016 Jul; 61():85-93. PubMed ID: 27155447
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Association Between Use of the 21-Gene Recurrence Score Assay and Receipt of Chemotherapy Among Medicare Beneficiaries With Early-Stage Breast Cancer, 2005-2009.
    Dinan MA; Mi X; Reed SD; Lyman GH; Curtis LH
    JAMA Oncol; 2015 Nov; 1(8):1098-109. PubMed ID: 26313372
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Use of 70-gene signature to predict prognosis of patients with node-negative breast cancer: a prospective community-based feasibility study (RASTER).
    Bueno-de-Mesquita JM; van Harten WH; Retel VP; van 't Veer LJ; van Dam FS; Karsenberg K; Douma KF; van Tinteren H; Peterse JL; Wesseling J; Wu TS; Atsma D; Rutgers EJ; Brink G; Floore AN; Glas AM; Roumen RM; Bellot FE; van Krimpen C; Rodenhuis S; van de Vijver MJ; Linn SC
    Lancet Oncol; 2007 Dec; 8(12):1079-1087. PubMed ID: 18042430
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Use and Impact of the 21-Gene Recurrence Score in Relation to the Clinical Risk of Developing Metastases in Early Breast Cancer Patients in the Netherlands.
    Schreuder K; Kuijer A; Bentum S; van Dalen T; Siesling S
    Public Health Genomics; 2018; 21(1-2):85-92. PubMed ID: 30650410
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Changing Role of Gene-Expression Profiling in the Era of De-escalating Adjuvant Chemotherapy in Early-Stage Breast Cancer.
    van Steenhoven JEC; Kuijer A; Schreuder K; Elias SG; van Diest PJ; van der Wall E; Siesling S; van Dalen T
    Ann Surg Oncol; 2019 Oct; 26(11):3495-3501. PubMed ID: 31209664
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Population-Based Study to Determine the Health System Costs of Using the 21-Gene Assay.
    Mittmann N; Earle CC; Cheng SY; Julian JA; Rahman F; Seung SJ; Levine MN
    J Clin Oncol; 2018 Jan; 36(3):238-243. PubMed ID: 29193984
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Association of 70-Gene Signature Assay Findings With Physicians' Treatment Guidance for Patients With Early Breast Cancer Classified as Intermediate Risk by the 21-Gene Assay.
    Tsai M; Lo S; Audeh W; Qamar R; Budway R; Levine E; Whitworth P; Mavromatis B; Zon R; Oldham D; Untch S; Treece T; Blumencranz L; Soliman H
    JAMA Oncol; 2018 Jan; 4(1):e173470. PubMed ID: 29075751
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Underdiagnosis of Hereditary Breast Cancer: Are Genetic Testing Guidelines a Tool or an Obstacle?
    Beitsch PD; Whitworth PW; Hughes K; Patel R; Rosen B; Compagnoni G; Baron P; Simmons R; Smith LA; Grady I; Kinney M; Coomer C; Barbosa K; Holmes DR; Brown E; Gold L; Clark P; Riley L; Lyons S; Ruiz A; Kahn S; MacDonald H; Curcio L; Hardwick MK; Yang S; Esplin ED; Nussbaum RL
    J Clin Oncol; 2019 Feb; 37(6):453-460. PubMed ID: 30526229
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of 70-Gene Signature Use on Adjuvant Chemotherapy Decisions in Patients With Estrogen Receptor-Positive Early Breast Cancer: Results of a Prospective Cohort Study.
    Kuijer A; Straver M; den Dekker B; van Bommel ACM; Elias SG; Smorenburg CH; Wesseling J; Linn SC; Rutgers EJT; Siesling S; van Dalen T
    J Clin Oncol; 2017 Aug; 35(24):2814-2819. PubMed ID: 28813638
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Adjuvant systemic therapy in early breast cancer: impact of guideline changes and clinicopathological factors associated with nonadherence at a nation-wide level.
    Verschoor AM; Kuijer A; Verloop J; Van Gils CH; Sonke GS; Jager A; van Dalen T; Elias SG
    Breast Cancer Res Treat; 2016 Sep; 159(2):357-65. PubMed ID: 27514397
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Population-based study of the effect of gene expression profiling on adjuvant chemotherapy use in breast cancer patients under the age of 65 years.
    Potosky AL; O'Neill SC; Isaacs C; Tsai HT; Chao C; Liu C; Ekezue BF; Selvam N; Kessler LG; Zhou Y; Schwartz MD
    Cancer; 2015 Nov; 121(22):4062-70. PubMed ID: 26291519
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Influence of integrated molecular pathology test results on real-world management decisions for patients with pancreatic cysts: analysis of data from a national registry cohort.
    Loren D; Kowalski T; Siddiqui A; Jackson S; Toney N; Malhotra N; Haddad N
    Diagn Pathol; 2016 Jan; 11():5. PubMed ID: 26790950
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tamoxifen therapy benefit predictive signature coupled with prognostic signature of post-operative recurrent risk for early stage ER+ breast cancer.
    Cai H; Li X; Li J; Ao L; Yan H; Tong M; Guan Q; Li M; Guo Z
    Oncotarget; 2015 Dec; 6(42):44593-608. PubMed ID: 26527319
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of Oncotype DX breast Recurrence Score testing on adjuvant chemotherapy use in early breast cancer: Real world experience in Greater Manchester, UK.
    Loncaster J; Armstrong A; Howell S; Wilson G; Welch R; Chittalia A; Valentine WJ; Bundred NJ
    Eur J Surg Oncol; 2017 May; 43(5):931-937. PubMed ID: 28111076
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Calibration and discriminatory accuracy of prognosis calculation for breast cancer with the online Adjuvant! program: a hospital-based retrospective cohort study.
    Mook S; Schmidt MK; Rutgers EJ; van de Velde AO; Visser O; Rutgers SM; Armstrong N; van't Veer LJ; Ravdin PM
    Lancet Oncol; 2009 Nov; 10(11):1070-6. PubMed ID: 19801202
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Do online prognostication tools represent a valid alternative to genomic profiling in the context of adjuvant treatment of early breast cancer? A systematic review of the literature.
    El Hage Chehade H; Wazir U; Mokbel K; Kasem A; Mokbel K
    Am J Surg; 2018 Jan; 215(1):171-178. PubMed ID: 28622841
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.